CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向 KRAS 突变肺癌

Targeting KRAS-Mutant Lung Cancers.

CD200-CD200R 作为实体瘤中的髓系免疫检查点：机制、情境依赖性功能及治疗机会

CD200-CD200R as a myeloid immune checkpoint in solid tumors: mechanisms, context-dependent functions, and therapeutic opportunities.

T 细胞重定向疗法在肺癌中的应用——临床试验的综合分析

T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials.

无可靶向基因组变异且从未吸烟的非小细胞肺癌患者中 PD-(L)1 阻断的临床结局与缓解预测因素

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

我们展示了联合治疗如何可能改善 AGA 阴性且无烟草暴露史的非小细胞肺癌患者的免疫检查点抑制剂（ICI）治疗结局。

NSCLC 精准免疫肿瘤学：整合 ADC、治疗性疫苗与过继性细胞治疗用于下一代全身治疗

Precision immuno-oncology in NSCLC: integrating ADCs, therapeutic vaccines, and adoptive cell therapies for next-generation systemic treatment.

一种新型 CAF 群体在肺癌中协调高抑制性调节性 T 细胞的募集和定位

A novel CAF population coordinates hyper-suppressive regulatory T cell recruitment and localization in lung cancer.

消退相关巨噬细胞募集限制靶向治疗耐药的 NK 细胞

Regression-Associated Macrophages Recruit Natural Killer Cells that Constrain Targeted Therapy Resistance.

评估 IL-17 阻断抗体在植入性和 UVB 诱导性癌症中与检查点抑制剂或肿瘤特异性 T 细胞联合的肿瘤免疫治疗中的作用

Assessment of Blocking Interleukin-17 Antibodies in Tumor Immunotherapy with Checkpoint Inhibitors or Tumor-Specific T Cells in Implanted and UVB-Indu

蛋白质组学分析鉴定 CLDN3 为小细胞肺癌的肿瘤选择性治疗靶点

Proteomic Profiling Identifies CLDN3 as a Tumor-Selective Therapeutic Target in Small Cell Lung Cancer.

PD-1 阻断后肿瘤浸润浆细胞分析揭示肿瘤特异性抗体

Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.